Impact of a probiotic-based hospital sanitation on antimicrobial resistance and HAI-associated antimicrobial consumption and costs: a multicenter study.
AMR
HAI
antimicrobials
costs
drug consumption
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
19
3
2019
pubmed:
19
3
2019
medline:
19
3
2019
Statut:
epublish
Résumé
Antimicrobial resistance (AMR) is one of the major threats to human health, and the high frequency of resistant pathogens in the hospital environment can contribute to the transmission of difficult-to-treat health care-associated infections (HAIs). We recently reported that, compared with conventional chemical cleaning, the use of a microbial-based sanitation strategy (Probiotic Cleaning Hygiene System [PCHS]) was associated with remodulation of hospital microbiota and reduction of HAI incidence. Here, we aimed to analyze the impact of PCHS on AMR and related effects, such as HAI-associated antimicrobial drug consumption and costs. Five Italian hospitals, enrolled in a multicenter study where conventional sanitation methods were replaced with PCHS, were included in the analysis. The study period included a 6-month observation for each sanitation type. Surface microbiota AMR was analyzed using microarray, nested PCR, antibiogram, and microdilution tests. Drug consumption data and related costs were obtained from the medical records of all hospitalized patients affected by HAIs. PCHS use was associated with up to 99% decrease of the AMR genes harbored by surface hospital microbiota, independently of the resistance types originally present in each individual setting ( The spread of AMR in the hospital environment can be limited by the use of sanitation methods to remodulate the hospital microbiota, leading to lower antimicrobial consumption and costs. This approach might be considered as part of broader infection prevention and control strategies.
Identifiants
pubmed: 30881055
doi: 10.2147/IDR.S194670
pii: idr-12-501
pmc: PMC6398408
doi:
Types de publication
Journal Article
Langues
eng
Pagination
501-510Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
Clin Infect Dis. 2004 Oct 15;39(8):1182-9
pubmed: 15486843
BMC Infect Dis. 2006 Aug 16;6:130
pubmed: 16914034
J Hosp Infect. 2007 Jun;65 Suppl 2:50-4
pubmed: 17540242
J Hosp Infect. 2009 Dec;73(4):378-85
pubmed: 19726106
Am J Infect Control. 2010 Jun;38(5 Suppl 1):S25-33
pubmed: 20569853
Lancet. 2011 Jan 15;377(9761):228-41
pubmed: 21146207
Infect Control Hosp Epidemiol. 2011 Jul;32(7):687-99
pubmed: 21666400
Euro Surveill. 2013 Jan 10;18(2):null
pubmed: 23324427
Curr Opin Infect Dis. 2013 Aug;26(4):338-44
pubmed: 23743816
Infect Control Hosp Epidemiol. 2014 Jul;35(7):855-65
pubmed: 24915214
PLoS One. 2014 Sep 26;9(9):e108598
pubmed: 25259528
Clin Microbiol Rev. 2014 Oct;27(4):665-90
pubmed: 25278571
Int J Infect Dis. 2015 Feb;31:31-4
pubmed: 25528484
Med Mal Infect. 2015 Apr;45(4):133-8
pubmed: 25725924
PLoS One. 2016 Feb 17;11(2):e0148857
pubmed: 26886448
J Hosp Infect. 2016 Jul;93(3):263-70
pubmed: 27140421
Microb Biotechnol. 2017 Sep;10(5):1079-1083
pubmed: 28677216
PLoS One. 2018 Jul 12;13(7):e0199616
pubmed: 30001345
Emerg Infect Dis. 2018 Sep;24(9):1752-1753
pubmed: 30124425